Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here to find out why VRTX is a Buy.
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...
Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of ...
The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Scientists from James Cook University have developed a new computer tool that reveals layers of gene activity that were ...
As previously reported, Leerink upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a price target of $456, down from ...
Firaxis and 2K continue to twiddle with Civilization 7's exploration phase, adding new map generators that produce more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback